• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, Q1 2011 - Product Image

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, Q1 2011

  • Published: March 2011
  • Region: Global
  • 167 pages
  • Global Markets Direct

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, Q1 2011', provides an overview of the Chronic Lymphocytic Leukemia (CLL) therapeutic pipeline. This report provides information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL). 'Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chronic Lymphocytic Leukemia (CLL).
- READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Lymphocytic Leukemia (CLL) Overview
Therapeutics Development
An Overview of Pipeline Products for Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia (CLL) Therapeutics under Development by Companies
Chronic Lymphocytic Leukemia (CLL) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Chronic Lymphocytic Leukemia (CLL) Therapeutics - Products under Development by Companies
Chronic Lymphocytic Leukemia (CLL) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Chronic Lymphocytic Leukemia (CLL) Therapeutics Development
Genzyme Corporation
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd.
Abbott Laboratories
Biogen Idec Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Seattle Genetics, Inc.
Gilead Sciences, Inc.
Merck & Co., Inc.
Emergent BioSolutions Inc.
Lentigen Corporation
Takeda Pharmaceutical Company Limited
Novartis AG
Genta Incorporated
Nippon Shinyaku Co., Ltd.
PDL BioPharma, Inc.
Sunesis Pharmaceuticals, Inc.
Genmab A/S
Santaris Pharma A/S
Astex Therapeutics Limited
Celgene Corporation
Quintiles Transnational Corp.
Bayer AG
AEterna Zentaris Inc.
IMMUNOMEDICS, INC
InNexus Biotechnology Inc.
MethylGene Inc
Alexion Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc.
Portola Pharmaceuticals, Inc.
Transcept Pharmaceuticals, Inc.
TopoTarget A/S
Pharmacyclics, Inc.
MorphoSys AG
Threshold Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Protox Therapeutics Inc.
SymBio Pharmaceuticals Limited
Kantonsspital Aarau AG
Baylor College of Medicine
InDex Pharmaceuticals AB
Memgen, LLC.
Calistoga Pharmaceuticals, Inc.
Curacyte AG
MAT Biopharma
Aegera Therapeutics Inc.
Ascenta Therapeutics, Inc.
Arno Therapeutics, Inc.
Fresenius Biotech GmbH
Semafore Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, LLC
Polyphenon Pharma
Onconova Therapeutics, Inc
Gemin X Pharmaceuticals
SBI Biotech Co., Ltd.
KaloBios Pharmaceuticals, Inc.
Cylene Pharmaceuticals, Inc.
Biothera
Nereus Pharmaceuticals, Inc.
Chronic Lymphocytic Leukemia Research Consortium
Laboratoire français de Fractionnement et de Biotechnologies
Advancell
Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Genasense - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Arzerra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SyB L-0501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludara - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Campath + Fludara - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Revlimid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Genasense + Fludarabine + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Flucam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Arzerra + Fludarabine + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ofatumumab + Chlorambucil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Cyclophosphamide + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RO5072759 + Chlorambucil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Fludarabine + (Cyclophosphamide + Rituximab) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + (Cyclophosphamide + Campath) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chlorambucil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludara + Cytoxan + Rituxan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nipent + Cytoxan + Rituxan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Radiation Therpay + Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine Phosphate + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine phosphate + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Fludarabine + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Darbepoetin alfa + Fludarabine phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fludarabine + cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclosporin + Methylprednisolone + Umbilical Cord Blood Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alemtuzumab + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Cyclophosphamide + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chlorambucil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thiotepa + Cyclophosphamide + ATG + OKT3 + Rituximab + Radiation therapy + Stem cell tranplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Cyclophosphamide + Rituximab + Lenalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Procrit - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Cyclophosphamide + Fludarabine Phosphate + Mitoxantrone Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Cyclophosphamide + Fludarabine Phosphate + Mitoxantrone Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cyclophosphamide + fludarabine phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab + cyclophosphamide + fludarabine phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab + fludarabine phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alemtuzumab + rituximab + cyclophosphamide + fludarabine phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bendamustine + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chronic Lymphocytic Leukemia (CLL) Therapeutics - Discontinued Products
Chronic Lymphocytic Leukemia (CLL) - Featured News
Dec 09, 2010: Memgen Presents Clinical And Preclinical Results Of Oncology Drug At ASH Annual Meeting
Dec 07, 2010: Pharmacyclics Reports Updated Clinical Results From Phase IA Trial Of PCI-32765
Dec 06, 2010: Aeterna Zentaris Reports Preclinical And Interim Results Of Phase II Of Perifosine In Treatment Of Advanced Leukemia
Dec 06, 2010: Aeterna Zentaris Presents Phase II Data Of Perifosine In Combination With Sorafenib In Advanced Leukemia And Lymphoma
Dec 06, 2010: Emergent Presents Positive Data From TRU-016 Program At American Society Of Hematology Meeting
Dec 05, 2010: Alexion Reports Positive Interim Results From Phase I/II Trial Of Samalizumab
Dec 05, 2010: Calistoga Reports Positive Results From CAL-101 Phase I Trial In Hematologic Malignancies
Dec 05, 2010: Calistoga Reports Positive Phase I interim Results From Combination Trial Of CAL-101 In Hematologic Malignancies
Dec 05, 2010: Pharmacyclics Reports Positive Results From Phase I Study Of PCI-32765 At ASH Annual Meeting
Dec 05, 2010: Pharmacyclics Reports Preclinical Data Of PCI-32765 In Chronic Lymphocytic Leukemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Chronic Lymphocytic Leukemia (CLL), Q1 2011
Products under Development for Chronic Lymphocytic Leukemia (CLL) – Comparative Analysis, Q1 2011
Comparative Analysis by Late Stage Development, Q1 2011
Comparative Analysis by Mid Clinical Stage Development, Q1 2011
Comparative Analysis by Early Clinical Stage Development, Q1 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q1 2011
Genzyme Corporation, 2011
Johnson & Johnson, 2011
F. Hoffmann-La Roche Ltd., 2011
Kyowa Hakko Kirin Co., Ltd., 2011
Abbott Laboratories, 2011
Biogen Idec Inc., 2011
AstraZeneca PLC, 2011
Eli Lilly and Company, 2011
GlaxoSmithKline plc, 2011
Seattle Genetics, Inc., 2011
Gilead Sciences, Inc., 2011
Merck & Co., Inc., 2011
Emergent BioSolutions Inc., 2011
Lentigen Corporation, 2011
Takeda Pharmaceutical Company Limited, 2011
Novartis AG, 2011
Genta Incorporated, 2011
Nippon Shinyaku Co., Ltd., 2011
PDL BioPharma, Inc., 2011
Sunesis Pharmaceuticals, Inc., 2011
Genmab A/S, 2011
Santaris Pharma A/S, 2011
Astex Therapeutics Limited, 2011
Celgene Corporation, 2011
Quintiles Transnational Corp., 2011
Bayer AG, 2011
AEterna Zentaris Inc., 2011
IMMUNOMEDICS, INC, 2011
InNexus Biotechnology Inc., 2011
MethylGene Inc, 2011
Alexion Pharmaceuticals, Inc., 2011
BioCryst Pharmaceuticals, Inc., 2011
Portola Pharmaceuticals, Inc., 2011
Transcept Pharmaceuticals, Inc., 2011
TopoTarget A/S, 2011
Pharmacyclics, Inc., 2011
MorphoSys AG, 2011
Threshold Pharmaceuticals, Inc., 2011
Synta Pharmaceuticals Corp., 2011
Protox Therapeutics Inc., 2011
SymBio Pharmaceuticals Limited, 2011
Kantonsspital Aarau AG, 2011
Baylor College of Medicine, 2011
InDex Pharmaceuticals AB, 2011
Memgen, LLC., 2011
Calistoga Pharmaceuticals, Inc., 2011
Curacyte AG, 2011
MAT Biopharma, 2011
Aegera Therapeutics Inc., 2011
Ascenta Therapeutics, Inc., 2011
Arno Therapeutics, Inc., 2011
Fresenius Biotech GmbH, 2011
Semafore Pharmaceuticals, Inc., 2011
Deciphera Pharmaceuticals, LLC, 2011
Polyphenon Pharma, 2011
Onconova Therapeutics, Inc, 2011
Gemin X Pharmaceuticals, 2011
SBI Biotech Co., Ltd., 2011
KaloBios Pharmaceuticals, Inc., 2011
Cylene Pharmaceuticals, Inc., 2011
Biothera, 2011
Nereus Pharmaceuticals, Inc., 2011
Chronic Lymphocytic Leukemia Research Consortium, 2011
Laboratoire français de Fractionnement et de Biotechnologies, 2011
Advancell, 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Discontinued Products

List of Figures
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), Q1 2011
Products under Development for Chronic Lymphocytic Leukemia (CLL) – Comparative Analysis, Q1 2011
Products under Development by Companies, Q1 2011
Products under Investigation by Universities/Institutes, Q1 2011
Late Stage Products, Q1 2011
Mid Clinical Stage Products, Q1 2011
Early Clinical Stage Products, Q1 2011
Discovery and Pre-Clinical Stage Products, Q1 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Combination Products, Q1 2011
Assessment by Route of Administration, Q1 2011
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Assessment by Stage and Molecule Type, Q1 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos